Understanding the roles of the kynurenine pathway in multiple sclerosis progression

Chai K. Lim, Bruce J. Brew, Gayathri Sundaram, Gilles J. Guillemin*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

43 Citations (Scopus)
27 Downloads (Pure)


The kynurenine pathway (KP) is a major degradative pathway of tryptophan ultimately leading to the production of nicotinamide adenine dinucleotide (NAD +) and is also one of the major regulatory mechanisms of the immune response. The KP is known to be involved in several neuroinflammatory disorders including Alzheimer's disease, amyotrophic lateral sclerosis, AIDS dementia complex, Parkinson's disease, schizophrenia, Huntington's disease and brain tumours. However, the KP remains a relatively new topic for the field of multiple sclerosis (MS). Over the last 2-3 years, some evidence has progressively emerged suggesting that the KP is likely to be involved in the pathogenesis of autoimmune diseases especially MS. Some KP modulators are already in clinical trials for other inflammatory diseases and would potentially provide a new and important therapeutic strategy for MS patients. This review summarizes the known relationships between the KP and MS.

Original languageEnglish
Pages (from-to)157-167
Number of pages11
JournalInternational Journal of Tryptophan Research
Issue number1
Publication statusPublished - 2010
Externally publishedYes

Bibliographical note

Copyright the Author(s), publisher and licensee Libertas Academica Ltd. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.


Dive into the research topics of 'Understanding the roles of the kynurenine pathway in multiple sclerosis progression'. Together they form a unique fingerprint.

Cite this